Category: Components



IntriCon Reports 20% Sales Gain in Third Quarter 2018

For the 2018 third quarter, the company reported net sales of $30.1 million, up 20.2% from $25.1 million in the prior-year period. According to the announcement, the increase was primarily due to year-over-year revenue gains from IntriCon’s largest medical customer and growth in its value-based hearing healthcare business.

Bragi Releases the Dash Pro Tailored by Starkey and the Dash Pro Hearables

The two new members of the Bragi family include The Dash Pro tailored by Starkey, “The World’s First Custom-Made Wireless Ear Computer,” featuring a unique, personalized experience, and The Dash Pro, a polished, reloaded, re-engineered sequel to The Dash that continues to press innovation forward.

Read More

Phonak Communications Launches New Features for Roger Earpiece

Phonak Communications, Murten, Switzerland—a telecommunications equipment supplier—has increased the functionality and flexibility of the successful Roger Earpiece launched in 2016 with an unlimited range extension facility, the company announced. From July 2017, it will be possible to have full coverage wherever you are, including across multiple rooms, such as from green room to main stage.

Read More

Sensaphonics Announces ‘New Product Release’ on April 1

Sensaphonics announced on April 1 the Perceptuator IEM plug-in accessory, the latest advancement in safe sound for musicians. Designed to make 65 dB sound like 100 dB, Sensaphonics says the Perceptuator plugs directly into your brain, and uses your own powerful sense memories to make you feel like you’re rocking your brains out while delivering studio reference sound quality at safe levels.

Read More

Study Shows Hair Cell Regrowth with New Drug

A new approach, published in “Cell Reports,” to regenerate inner ear sensory hair cells is said to lay the groundwork for treating chronic noise-induced hearing loss by the company, Frequency Therapeutics, and its co-founders who are drawing on research from Brigham and Women’s Hospital (BWH), Harvard Medical School, Mass Eye and Ear Infirmary, and MIT. The program is expected to progress to into human clinical trials within the next 18 months.

Read More